research Episodes of Keratitis during Treatment with Baricitinib for Alopecia Areata
Baricitinib for alopecia areata may rarely cause eye issues like keratitis.
Search
for
Sort by
Research
900-930 / 1000+ resultsresearch The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research Dermatologic therapy: December 1986 to December 1987
Various dermatologic treatments were effective for skin conditions like acne, rosacea, hair loss, and psoriasis from December 1986 to December 1987.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research Erosive pustular dermatosis of the scalp following topical latanoprost for androgenetic alopecia
Latanoprost may cause scalp inflammation and delayed healing.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
research Association of androgenetic alopecia with metabolic syndrome in men: a community-based survey
Balding men, especially young ones, may have higher risk of heart issues and diabetes; check cholesterol levels.
research Androgenetic alopecia; An attempt to target microinflammation
Reducing micro-inflammation didn't change hair growth patterns in AGA.
research 63-Year-Old Female with Diffuse Thinning of the Hair
Androgenetic alopecia, a common hair loss condition, can be treated with topical minoxidil, oral finasteride, or oral spironolactone, and new treatments like platelet-rich plasma, low-level laser therapy, and janus-kinase inhibitors are being explored.
research Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost
Latanoprost eye drops caused excessive hair growth and eyelash whitening in a woman.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Alopecia Areata: Current Treatments and New Directions
JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.
research Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up
Finasteride effectively increases hair growth in men with AGA, works better for those over 30, and may cause some side effects.
research Multi-target evaluation of Korean herbal compounds against the SRD5A2 / AR / beta-catenin axis for androgenetic alopecia: Boltz-2 cofold, ChEMBL-anchored ranking, ADMET-AI 107-endpoint safety panel, and pilosebaceous single-cell atlas-constrained prioritization of Saponin Re, Emodin, and Biochanin A
Biochanin A from soy is a promising and safe candidate for treating hair loss.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Androgenetic Alopecia: Therapy Update
There are many treatments for common hair loss, but more trials are needed to decide which are best.
research Hairy tongue associated with the use of baricitinib therapy for ophiasis pattern alopecia areata
A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Uncovering novel biomarkers and drug targets for androgenetic alopecia via metabolite regulation and multi-tissue validation
SOD1 and KL are promising targets for new hair loss treatments.
research Androgenetic Alopecia Treatment in Asian Men.
The treatment is safe and very effective for hair growth in Asian men with minimal side effects.
research Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research Clobetasol/minoxidil
research From Hairline to Lipid Line: Prevalence and Spectrum of Dyslipidemia in Patients with Androgenetic Alopecia – A Hospital-Based Study
Patients with androgenetic alopecia often have abnormal lipid levels, so they should be screened and advised on lifestyle changes to prevent heart issues.
research Clinical efficacy of supplement and scalp lotion containing astaxanthin in male androgenetic alopecia
research Jak inhibitors in the treatment of alopecia areata - a literature review
Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
research Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
research The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double‐blind placebo‐controlled trial
Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.
research Baricitinib in Alopecia Areata
Baricitinib is not very effective for severe alopecia areata.